3 Health Care Stocks Moving The Sector Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 105 points (0.6%) at 16,554 as of Tuesday, April 22, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,226 issues advancing vs. 749 declining with 155 unchanged.

The Health Care sector currently sits up 2.7% versus the S&P 500, which is up 0.6%. Top gainers within the sector include Allergan ( AGN), up 15.7%, Intercept Pharmaceuticals ( ICPT), up 14.4%, Shire ( SHPG), up 5.7%, Valeant Pharmaceuticals International ( VRX), up 5.6% and Vertex Pharmaceuticals ( VRTX), up 4.6%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Pfizer ( PFE) is one of the companies pushing the Health Care sector higher today. As of noon trading, Pfizer is up $0.36 (1.2%) to $31.22 on average volume. Thus far, 14.6 million shares of Pfizer exchanged hands as compared to its average daily volume of 28.8 million shares. The stock has ranged in price between $30.85-$31.25 after having opened the day at $30.85 as compared to the previous trading day's close of $30.86.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. Pfizer has a market cap of $193.4 billion and is part of the drugs industry. Shares are up 0.8% year-to-date as of the close of trading on Monday. Currently there are 8 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Johnson & Johnson ( JNJ) is up $0.69 (0.7%) to $100.69 on average volume. Thus far, 4.3 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.0 million shares. The stock has ranged in price between $99.74-$100.73 after having opened the day at $100.00 as compared to the previous trading day's close of $100.00.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $279.9 billion and is part of the drugs industry. Shares are up 9.2% year-to-date as of the close of trading on Monday. Currently there are 8 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $1.39 (1.9%) to $72.99 on average volume. Thus far, 11.7 million shares of Gilead exchanged hands as compared to its average daily volume of 15.7 million shares. The stock has ranged in price between $71.85-$73.25 after having opened the day at $72.86 as compared to the previous trading day's close of $71.60.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $107.6 billion and is part of the drugs industry. Shares are down 4.7% year-to-date as of the close of trading on Monday. Currently there are 18 analysts who rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error